IFN specialization is also evident in the clinical use of recombinant subtypes, with IFNB1 being the most effective for the treatment of multiple sclerosis, whereas IFNA2 preparations are preferred for the treatment of chronic viral infections and some malignancies (48). This evidence concerns the gene IFNA2 and multiple sclerosis.